"With IRB approval we can proceed to take the final steps toward launching the N1 Registry," said Dr. Dane J. Dickson, M.D., and CEO of MED-C. "We are confident our efforts will contribute significantly to the Moonshot's challenges to enhance data sharing and improve clinical trials processes."
MED-C's registry will be overseen by an investigator core of 15 internationally recognized hematology and oncology leaders and closely monitored by key industry organizations as a potential disruptive innovation in precision medicine.
A summary of the protocol is recorded on ClinicalTrials.gov, entitled "Patients Diagnosed with Advanced Malignancy or Myelodysplasia, Tested by Standardized Sequencing, and Treated by Physician-Determined Care Plan: A MED-C Observational Registry (N1)"
MED-C is a nonprofit organization aiming to unify all key medical stakeholders to advance precision medicine through its N1 Registry that will contain standardized, high-quality, next-generation sequencing combined with clinical outcomes.
This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/med-cs-groundbreaking-ngs-registry-gets-irb-approval-300325827.html